â– LECTURE OVERVIEW: Methotrexate (MTX) is a high-yield folate antagonist chemotherapeutic agent utilized at varying doses for oncological, gynecological, and rheumatological indications.
â– CHEMOTHERAPEUTIC MECHANISMS:
1. Enzyme Overdrive Inhibition: MTX is a structural analog of folic acid, binding with over 1000-fold affinity to the active site of Dihydrofolate Reductase (DHFR).
2. Tetrahydrofolate Depletion: This completely prevents the conversion of dihydrofolate (DHF) to active tetrahydrofolate (THF).
3. Thymidylate Synthesis Arrest: THF is the essential one-carbon carrier required for de novo purine synthesis and the conversion of dUMP to dTMP by thymidylate synthase.
4. Replication Halt: Depleted thymidine halts eukaryotic DNA replication, arresting rapidly dividing malignant cell lines or placental trophoblastic cells.
â– IMMUNOLOGICAL & CYTOKINE SIGNALLING FLUX:
Pathogen exposure or cellular distress triggers antigen-presenting cell activation. This results in the release of pro-inflammatory cytokines (such as IL-1, TNF-alpha, and IL-6) and triggers receptor-mediated cellular chemotaxis.
â– DIAGNOSTIC FLOW ALGORITHM:
When initial screening yields ambiguous results, utilize highly discrete confirmatory assays or magnetic imaging sweeps to establish structural parameters.
[HY-BOARD-1276]
🌟 Dynamic Clinical Key:
High-dose MTX therapy can devastate healthy rapidly dividing tissue, primarily bone marrow (pancytopenia) and gastrointestinal mucosa (mucositis). To prevent fatal toxicity, Leucovorin (Folinic Acid) is administered. Leucovorin is a reduced folate derivative that bypasses the blocked DHFR enzyme, directly restoring intracellular folate pools in healthy cells. Target specific monoclonal antibodies or immune suppressors to control the hyper-inflammatory cascade. Avoid premature diagnostic closure before reviewing all essential imaging planes.